Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
Russian Federation
Study Type
Interventional
Intervention
Aliskiren/ Valsartan
Telmisartan/ Ramipril
Sponsored by

About this trial
This is an interventional basic science trial for Hypertension focused on measuring Aliskiren,, hypertension,, renin-angiotensin-aldosterone system
Eligibility Criteria
Inclusion Criteria:
- Males or females of non-childbearing potential, 18 to 65 years of age with moderate hypertension
- Patients who are eligible and able to participate in the study
Exclusion criteria:
- Severe hypertension or secondary form of hypertension.
- Serum potassium > 5.1 mEq/L (mmol/L)
- Heart failure
- Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention
- Uncontrolled or life-threatening arrythmia
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- Novartis Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Aliskiren and Valsartan
Telmisartan and Ramipril
Arm Description
Outcomes
Primary Outcome Measures
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone
Secondary Outcome Measures
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure
Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan
Full Information
NCT ID
NCT00939588
First Posted
July 9, 2009
Last Updated
November 16, 2016
Sponsor
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00939588
Brief Title
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
Official Title
An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Aliskiren,, hypertension,, renin-angiotensin-aldosterone system
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
88 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Aliskiren and Valsartan
Arm Type
Experimental
Arm Title
Telmisartan and Ramipril
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Aliskiren/ Valsartan
Intervention Type
Drug
Intervention Name(s)
Telmisartan/ Ramipril
Primary Outcome Measure Information:
Title
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone
Time Frame
56 days
Secondary Outcome Measure Information:
Title
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on Plasma Renin Activity (PRA)and angiotensin II
Time Frame
56 days
Title
Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on mean sitting systolic and diastolic blood pressure
Time Frame
56 days
Title
Assess safety and tolerability of aliskiren + valsartan and ramipril + telmisartan
Time Frame
56 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or females of non-childbearing potential, 18 to 65 years of age with moderate hypertension
Patients who are eligible and able to participate in the study
Exclusion criteria:
Severe hypertension or secondary form of hypertension.
Serum potassium > 5.1 mEq/L (mmol/L)
Heart failure
Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention
Uncontrolled or life-threatening arrythmia
Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Moscow
Country
Russian Federation
12. IPD Sharing Statement
Learn more about this trial
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
We'll reach out to this number within 24 hrs